Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model

The aim of this study was to validate quantitative metabolic response of tumors to a treatment measured by longitudinal 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) micro positron emission tomography (microPET) as a robust tool for preclinical evaluation of new anticancer agents. Severe combined immunode...

Full description

Saved in:
Bibliographic Details
Published in:Molecular imaging and biology 2006-09, Vol.8 (5), p.300-308
Main Authors: Zhang, Yumin, Saylor, Melissa, Wen, Shenhua, Silva, Matthew D, Rolfe, Mark, Bolen, Joseph, Muir, Craig, Reimer, Corinne, Chandra, Sudeep
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - therapeutic use
Boronic Acids - therapeutic use
Bortezomib
Cancer
Cell Proliferation - drug effects
Drug Evaluation
Fluorodeoxyglucose F18 - pharmacokinetics
Humans
Longitudinal Studies
Male
Medical imaging
Mice
Mice, SCID
Organ Size - drug effects
Positron-Emission Tomography - methods
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - drug therapy
Pyrazines - therapeutic use
Radiation Dosage
Treatment Outcome
Tumor Cells, Cultured
Tumors
Xenograft Model Antitumor Assays
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to validate quantitative metabolic response of tumors to a treatment measured by longitudinal 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) micro positron emission tomography (microPET) as a robust tool for preclinical evaluation of new anticancer agents. Severe combined immunodeficiency mice with CWR22 xenografts were intravenously treated with bortezomib (Velcade) at 0.8 mg/kg on days 0, 3, 7, 10, and 14 and imaged with FDG microPET before, during and after treatment. Quantitative indices of tumor FDG uptake were developed. FDG microPET images successfully revealed the gradual reduction of tumor FDG uptake on day 4 onward despite no absolute tumor shrinkage. The standardized uptake values of FDG in tumors was reduced to 43% of the baseline values. Using the total tumor FDG uptake as the viable tumor burden, we found 86% tumor inhibition, compared to a 55% tumor growth inhibition in tumor volume measurement. FDG microPET imaging can provide an additional dimension of the efficacy of anticancer therapies that may otherwise be underestimated by tumor volume measurement.
ISSN:1536-1632
1860-2002
DOI:10.1007/s11307-006-0052-5